NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Breast Cancer Research and Treatment

Volumn 148, Issue 3, 2014, Pages 581-590

  Palmieri, C ^a   Cleator, S ^b   Kilburn, L S ^c   Kim, S B ^d   Ahn, S H ^d   Beresford, M ^e   Gong, G ^d   Mansi, J ^f   Mallon, E ^g   Reed, S ^h   Mousa, K ^h   Fallowfield, L ^j   Cheang, M ^c   Morden, J ^c   Page, K ⁱ   Guttery, D S ⁱ   Rghebi, B ⁱ   Primrose, L ⁱ   Shaw, J A ⁱ   Thompson, A M ^k   Bliss, J M ^c   Coombes, R C ^b   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d University of Ulsan College of Medicine   (South Korea)

^e ROYAL UNITED HOSPITAL   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j UNIVERSITY OF SUSSEX   (United Kingdom)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Breast; cfDNA; Ki 67; miRNA; Neoadjuvant therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; LET-7A MESSENGER RNA; LETROZOLE; MESSENGER RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; MICRORNA; MIRNLET7 MICRORNA, HUMAN; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIMARY TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; POSTMENOPAUSE; QUALITY OF LIFE; RECEPTORS, ESTROGEN; TRIAZOLES;

EID: 84911881708     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3183-4     Document Type: Article

References (34)

1. Kaufmann M, von Minckwitz G, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600–2608
2. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194
3. Colleoni M, Viale G, Zahrieh D et al (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10:6622–6628
4. Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32
5. Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633–640
6. Aebi S, Sun Z, Braun D et al (2011) Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 22:1981–1987
7. Viale G, Regan MM, Maiorano E et al (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors–International Breast Cancer Study Group. J Clin Oncol 26:1404–1410
8. Pagani O, Gelber S, Simoncini E et al (2009) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 116:491–500
9. Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658–1667
10. Palmieri C, Patten DK, Januszewski A et al (2014) Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol 382:695–723
11. Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527–1532
12. Cataliotti L, Buzdar AU, Noguchi S et al (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer 106:2095–2103
13. Krainick-Strobel UE, Lichtenegger W, Wallwiener D et al (2008) Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 8:62
14. Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J et al.(2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784
15. Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816
16. Clarke RB, Laidlaw IJ, Jones LJ et al (1993) Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67:606–611
17. Dowsett M, Ebbs SR, Dixon JM et al (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol 23:2477–2492
18. Dowsett M, Smith IE, Ebbs SR et al (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167–170
19. Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–1388
20. Semiglazov VF, Semiglazov VV, Dashyan GA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244–254
21. Shaw JA, Smith BM, Walsh T et al (2000) Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res 6:1119–1124
22. Hoque MO, Feng Q, Toure P et al (2006) Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24:4262–4269
23. Beaver JA, Jelovac D, Balukrishna S et al (2014) Detection of cancer DNA in plasma of early stage breast cancer patients. Clin Cancer Res 20(10):2643–2650
24. Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518
25. Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006
26. Yamamoto Y, Kosaka N, Tanaka M et al (2009) MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 14:529–538
27. Jung K, Fleischhacker M, Rabien A (2010) Cell-free DNA in the blood as a solid tumor biomarker–a critical appraisal of the literature. Clin Chim Acta 411:1611–1624
28. Shaw JA, Page K, Blighe K et al (2012) Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 22:220–231
29. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403(6772):901–906
30. Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR, Xiao GG (2011) Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 127:69–80
31. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109–1123
32. Sun X, Qin S, Fan C et al (2013) Let-7: a regulator of the ERalpha signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep 29:2079–2087
33. Semiglazov VF, Semiglazov VV, Dashyan GA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244–254
34. Alba E, Calvo L, Albanell J et al (2012) Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 23:3069–3074